Orchestra BioMed Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OBIO research report →
Range $10 – $10
Price Chart
About the company
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease.
- CEO
- David Hochman
- IPO
- 2020
- Employees
- 86
- HQ
- New Hope, PA, US
Get TickerSpark's AI analysis on OBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $555.26M
- P/E
- -7.93
- Fwd P/E
- 26.13
- PEG
- -0.10
- P/S
- 17.79
- P/B
- 24319.59
- EV/EBITDA
- -11.44
- Div Yield
- 0.00%
- Gross Margin
- 99.37%
- Op Margin
- -195.39%
- Net Margin
- -182.50%
- ROE
- -140.18%
- ROIC
- -64.63%
Latest fiscal year · YoY change
- Revenue
- $33.48M+1169.2%
- Gross Profit
- $33.29M+1267.8%
- Op Income
- $-51,807,000
- Net Income
- $-52,701,000+13.6%
- EPS
- $-1.11+33.1%
- OCF Growth
- +3.2%
- FCF Growth
- +2.7%
- Beta
- 0.55
- RSI (14)
- 61
No earnings-call transcripts are available for OBIO yet.
- Free Float
- 60.9%
- Shares Outstanding
- 78.70M
- Float Shares
- 47.94M
of shares held by institutions
81 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rtw Investments, LP | 9.56M | 0 |
| Perceptive Advisors LLC | 5.04M | ▼ 300 |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Americas LLC | 2.77M | ▲ 2.12M |
| Blackrock, Inc. | 2.72M | ▲ 204.66K |
| Vanguard Capital Management LLC | 2.00M | ▼ 20.20K |
| Vanguard Group Inc | 1.60M | ▲ 122.68K |
| Geode Capital Management, LLC | 1.00M | ▼ 3.91K |
| Masters Capital Management LLC | 1.00M | ▲ 1.00M |
| Propel Bio Management, LLC | 896.70K | 0 |
| Rice Hall James & Associates, LLC | 837.87K | ▲ 413.87K |
| State Street Corp | 605.78K | ▲ 89.73K |
| Ubs Group AG | 525.07K | ▲ 199.29K |
Held by 114 ETFs
Biggest fund positions in OBIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | RTW INVESTMENTS, LP | buy | 1,200,000 |
| Nov 9, 26 | Fain Eric S | buy | 20,000 |
| Nov 9, 26 | Pacitti David | buy | 20,000 |
| Nov 9, 26 | Hochman David P | buy | 5,000 |
| Nov 9, 26 | Taylor Andrew Lawrence | buy | 1,000 |
| Nov 2, 26 | Sherman Darren | sell | 15,000 |
| Oct 1, 26 | Sherman Darren | sell | 15,000 |
| Sep 10, 26 | Hochman David P | other | 3,283 |
| Sep 10, 26 | Hochman David P | other | 3,283 |
| Sep 3, 26 | Hochman David P | buy | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OBIO coverage
Recent articles, reports, and earnings notes.
No research on OBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OBIO report →